Beijing Chunlizhengda Medical Instruments (HKG:1858, SHA:688236) expects an attributable profit of between around 107.8 million yuan and 127.8 million yuan for the year 2024, down 54% to 61% from 277.8 million yuan, a year prior, a Friday bourse filing said.
The orthopedic medical device company attributed the lower anticipated profit mainly to a decline in revenue and net profit amid the continuous deepening of its centralized procurement policy leading to lower product prices and adjustments to the price of channel inventory.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。